The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ("monoclonal antibodies") have already pro- vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news- 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal, S 6 8 Business Week, Fortune,7 and The Economist,...